BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 24625004)

  • 61. FGFR4 polymorphism, TP53 mutation, and their combinations are prognostic factors for oral squamous cell carcinoma.
    Tanuma J; Izumo T; Hirano M; Oyazato Y; Hori F; Umemura E; Shisa H; Hiai H; Kitano M
    Oncol Rep; 2010 Mar; 23(3):739-44. PubMed ID: 20127014
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The FGFR4-388arg Variant Promotes Lung Cancer Progression by N-Cadherin Induction.
    Quintanal-Villalonga Á; Ojeda-Márquez L; Marrugal Á; Yagüe P; Ponce-Aix S; Salinas A; Carnero A; Ferrer I; Molina-Pinelo S; Paz-Ares L
    Sci Rep; 2018 Feb; 8(1):2394. PubMed ID: 29402970
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The Prognostic Significance of FGFR4 Gly388 Polymorphism in Esophageal Squamous Cell Carcinoma after Concurrent Chemoradiotherapy.
    Shim HJ; Shin MH; Kim HN; Kim JH; Hwang JE; Bae WK; Chung IJ; Cho SH
    Cancer Res Treat; 2016 Jan; 48(1):71-9. PubMed ID: 25989802
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Involvement of the FGFR4 Arg388 allele in head and neck squamous cell carcinoma.
    Streit S; Bange J; Fichtner A; Ihrler S; Issing W; Ullrich A
    Int J Cancer; 2004 Aug; 111(2):213-7. PubMed ID: 15197773
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Silencing of FGFR4 could influence the biological features of gastric cancer cells and its therapeutic value in gastric cancer.
    Ye Y; Jiang D; Li J; Wang M; Han C; Zhang X; Zhao C; Wen J; Kan Q
    Tumour Biol; 2016 Mar; 37(3):3185-95. PubMed ID: 26432329
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Compound deletion of Fgfr3 and Fgfr4 partially rescues the Hyp mouse phenotype.
    Li H; Martin A; David V; Quarles LD
    Am J Physiol Endocrinol Metab; 2011 Mar; 300(3):E508-17. PubMed ID: 21139072
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Cancer progression and tumor cell motility are associated with the FGFR4 Arg(388) allele.
    Bange J; Prechtl D; Cheburkin Y; Specht K; Harbeck N; Schmitt M; Knyazeva T; Müller S; Gärtner S; Sures I; Wang H; Imyanitov E; Häring HU; Knayzev P; Iacobelli S; Höfler H; Ullrich A
    Cancer Res; 2002 Feb; 62(3):840-7. PubMed ID: 11830541
    [TBL] [Abstract][Full Text] [Related]  

  • 68. ECRG1 and FGFR4 single nucleotide polymorphism as predictive factors for nodal metastasis in oral squamous cell carcinoma.
    Choi KY; Rho YS; Kwon KH; Chung EJ; Kim JH; Park IS; Lee DJ
    Cancer Biomark; 2012-2013; 12(3):115-24. PubMed ID: 23481570
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Targeting the ERK pathway for the treatment of Cushing's disease.
    Zhang D; Bergsneider M; Wang MB; Heaney AP
    Oncotarget; 2016 Oct; 7(43):69149-69158. PubMed ID: 27708250
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Polymorphisms of fibroblast growth factor receptor 4 have association with the development of prostate cancer and benign prostatic hyperplasia and the progression of prostate cancer in a Japanese population.
    Ma Z; Tsuchiya N; Yuasa T; Inoue T; Kumazawa T; Narita S; Horikawa Y; Tsuruta H; Obara T; Saito M; Satoh S; Ogawa O; Habuchi T
    Int J Cancer; 2008 Dec; 123(11):2574-9. PubMed ID: 18756523
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Self-regulation of Stat3 activity coordinates cell-cycle progression and neural crest specification.
    Nichane M; Ren X; Bellefroid EJ
    EMBO J; 2010 Jan; 29(1):55-67. PubMed ID: 19851287
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Fibroblast growth factor receptors display both common and distinct signaling pathways.
    Shaoul E; Reich-Slotky R; Berman B; Ron D
    Oncogene; 1995 Apr; 10(8):1553-61. PubMed ID: 7731710
    [TBL] [Abstract][Full Text] [Related]  

  • 73. FGFR4 Gene Polymorphism Reduces the Risk of Distant Metastasis in Lung Adenocarcinoma in Taiwan.
    Li JP; Huang HC; Yang PJ; Chang CY; Chao YH; Tsao TC; Huang H; Hung YC; Hsieh MJ; Yang SF
    Int J Environ Res Public Health; 2020 Aug; 17(16):. PubMed ID: 32781755
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Involvement of FGFR4 Gene Variants on the Clinicopathological Severity in Urothelial Cell Carcinoma.
    Tsay MD; Hsieh MJ; Lee CY; Wang SS; Chen CS; Hung SC; Lin CY; Yang SF
    Int J Environ Res Public Health; 2019 Dec; 17(1):. PubMed ID: 31878098
    [TBL] [Abstract][Full Text] [Related]  

  • 75. The receptor tyrosine kinase FGFR4 negatively regulates NF-kappaB signaling.
    Drafahl KA; McAndrew CW; Meyer AN; Haas M; Donoghue DJ
    PLoS One; 2010 Dec; 5(12):e14412. PubMed ID: 21203561
    [TBL] [Abstract][Full Text] [Related]  

  • 76. PAX3-FOXO1 and FGFR4 in alveolar rhabdomyosarcoma.
    Marshall AD; van der Ent MA; Grosveld GC
    Mol Carcinog; 2012 Oct; 51(10):807-15. PubMed ID: 21882254
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Functional FGFR4 Gly388Arg polymorphism predicts prognosis in lung adenocarcinoma patients.
    Spinola M; Leoni V; Pignatiello C; Conti B; Ravagnani F; Pastorino U; Dragani TA
    J Clin Oncol; 2005 Oct; 23(29):7307-11. PubMed ID: 16061909
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The ileal FGF15/19 to hepatic FGFR4 axis regulates liver regeneration after partial hepatectomy in mice.
    Li Q; Zhao Q; Zhang C; Zhang P; Hu A; Zhang L; Schroder PM; Ma Y; Guo Z; Zhu X; He X
    J Physiol Biochem; 2018 May; 74(2):247-260. PubMed ID: 29468415
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Targeting FGFR4 inhibits hepatocellular carcinoma in preclinical mouse models.
    French DM; Lin BC; Wang M; Adams C; Shek T; Hötzel K; Bolon B; Ferrando R; Blackmore C; Schroeder K; Rodriguez LA; Hristopoulos M; Venook R; Ashkenazi A; Desnoyers LR
    PLoS One; 2012; 7(5):e36713. PubMed ID: 22615798
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Identification of a novel oncogenic mutation of FGFR4 in gastric cancer.
    Futami T; Kawase T; Mori K; Asaumi M; Kihara R; Shindoh N; Kuromitsu S
    Sci Rep; 2019 Oct; 9(1):14627. PubMed ID: 31601997
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.